Henderson GE, Ewing M, Kuczynski KJ, Cadigan RJ, Waltz M, Butterfield RM, Rini C, Weck K, Berg JS, Edwards TP. Development and validation of a measure of comprehension of genomic screening-negative results (CoG-NR). Eur J Hum Gene. 2020 Oct;28(10):1394-402. doi: 10.1038/s41431-020-0657-1
Korsnes JS, Goodwin BB, Murray M, Candrilli SD. Antiretroviral treatment switching and its association with economic outcomes and adverse treatment effects among commercially insured and Medicaid-enrolled patients with HIV in the United States. Ann Pharmacother. 2016 Dec;50(12):989-1000.
Amend KL, Landon J, Thyagarajan (Hoffman) V, Niemcryk S, McAfee A. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Ann Pharmacother. 2011 Oct;45(10):1230-9. doi: 10.1345/aph.1Q110
Smith VK, Evans MF, Banzhaf HS, Poulos C. Can weak substitution be rehabilitated? Environ Resour Econ (Dordr). 2010 Feb 1;45(2):203-21.
Skinner CS, Schildkraut JM, Calingaert B, Hoyo C, Crankshaw SS, Fish L, Susswein L, Jasper C, Reid L. Factors associated with African Americans' enrollment in a national cancer genetics registry. Community Genet. 2008 Apr 1;11(4):224-33.
Nau DP, Steinke DT, Williams LK, Austin R, Lafata JE, Divine G, Pladevall-Vila M. Adherence analysis using visual analog scale versus claims-based estimation. Ann Pharmacother. 2007 Nov;41(11):1792-7.
Mansfield CA. Despairing over disparities: an empirical analysis of the relationship between willingness-to-pay and willingness-to-accept. Environ Resour Econ (Dordr). 1999;13(2):219-34.